PNC Financial Services Group Inc. Acquires 606 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

PNC Financial Services Group Inc. lifted its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 5.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,490 shares of the medical research company’s stock after purchasing an additional 606 shares during the period. PNC Financial Services Group Inc.’s holdings in Charles River Laboratories International were worth $2,716,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the business. Vanguard Group Inc. grew its holdings in Charles River Laboratories International by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 5,980,306 shares of the medical research company’s stock worth $1,413,744,000 after purchasing an additional 26,446 shares during the period. Wahed Invest LLC increased its position in Charles River Laboratories International by 9.5% in the 4th quarter. Wahed Invest LLC now owns 861 shares of the medical research company’s stock valued at $204,000 after buying an additional 75 shares in the last quarter. Polen Capital Management LLC raised its stake in Charles River Laboratories International by 26.4% during the 4th quarter. Polen Capital Management LLC now owns 6,328 shares of the medical research company’s stock worth $1,496,000 after buying an additional 1,323 shares during the period. FIL Ltd boosted its holdings in Charles River Laboratories International by 23.2% in the fourth quarter. FIL Ltd now owns 662,650 shares of the medical research company’s stock worth $156,650,000 after acquiring an additional 125,000 shares in the last quarter. Finally, Point72 Asset Management L.P. grew its stake in Charles River Laboratories International by 499.1% in the fourth quarter. Point72 Asset Management L.P. now owns 368,984 shares of the medical research company’s stock valued at $87,228,000 after acquiring an additional 307,398 shares during the period. Institutional investors and hedge funds own 98.91% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on CRL. Mizuho began coverage on Charles River Laboratories International in a report on Friday, June 7th. They issued a “neutral” rating and a $235.00 target price on the stock. TD Cowen reduced their price objective on shares of Charles River Laboratories International from $260.00 to $228.00 and set a “hold” rating for the company in a report on Monday, May 13th. The Goldman Sachs Group began coverage on shares of Charles River Laboratories International in a report on Thursday, June 6th. They issued a “buy” rating and a $290.00 target price on the stock. TheStreet upgraded Charles River Laboratories International from a “c+” rating to a “b-” rating in a research note on Friday, March 1st. Finally, Argus increased their price objective on Charles River Laboratories International from $240.00 to $290.00 and gave the stock a “buy” rating in a research note on Monday, March 18th. Six analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, Charles River Laboratories International has an average rating of “Moderate Buy” and an average target price of $256.38.

Insider Buying and Selling

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 1,304 shares of the stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $226.97, for a total transaction of $295,968.88. Following the completion of the transaction, the executive vice president now owns 23,276 shares in the company, valued at $5,282,953.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Price Performance

CRL opened at $209.63 on Friday. Charles River Laboratories International, Inc. has a fifty-two week low of $161.65 and a fifty-two week high of $275.00. The firm has a 50-day moving average of $223.07 and a 200 day moving average of $232.24. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.37 and a current ratio of 1.75. The firm has a market cap of $10.80 billion, a P/E ratio of 24.66, a PEG ratio of 1.98 and a beta of 1.40.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Thursday, May 9th. The medical research company reported $2.27 earnings per share for the quarter, beating analysts’ consensus estimates of $2.05 by $0.22. The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $997.24 million. Charles River Laboratories International had a net margin of 10.81% and a return on equity of 15.16%. On average, research analysts expect that Charles River Laboratories International, Inc. will post 11 EPS for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).